Background Image
Menu

Latest News

Rinicare’s SAFE falls reduction technology granted new UK patent

6 June 2022

Rinicare’s SAFE falls reduction technology granted new UK patent

SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year meaning an extra 110,000 older people are...

Trial to assess Acute Kidney Injury risk prediction technology starts at MFT

31 May 2022

Trial to assess Acute Kidney Injury risk prediction technology starts at MFT

A pioneering clinical trial of new technology to predict the risk of patients developing Acute Kidney Injury (AKI) has begun at Manchester University NHS Foundation Trust (MFT). The STABILITY UO (Urine Output) clinical risk prediction technology has been developed by Manchester...

Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022

31 May 2022

Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022

• Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally well tolerated with no dose-limiting toxicities observed; optimal dose selected at 3.0 mg/kg. • OBT076 showed...

NIHR backed AI care planning network goes live

30 May 2022

NIHR backed AI care planning network goes live

English healthcare providers are now able to join a network that uses crowd sourced data to shape care plans. Healum, an artificial intelligence-based App, uses data that patients have chosen to share in order to personalise care recommendations and improve clinical decision...

Oxford BioTherapeutics announces collaboration with Agenus

26 May 2022

Oxford BioTherapeutics announces collaboration with Agenus

Oxford BioTherapeutics announces collaboration with Agenus to support the clinical development of OBT’s antibody drug conjugate OBT076 in combination with Agenus’ CPI Balstilimab … • New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint...

CARB-X receives additional $370m from U.S. Government and Wellcome

26 May 2022

CARB-X receives additional $370m from U.S. Government and Wellcome

Funding will enable continued investment in innovative projects to tackle the growing global threat posed by AMR … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, welcomes the news that CARB-X (Combating Antibiotic...

Blueberry Therapeutics provides regulatory update on Phase 2b trial

25 May 2022

Blueberry Therapeutics provides regulatory update on Phase 2b trial

Alderley Park, 24 May 2022 – Blueberry Therapeutics has reported significant progress in its Phase 2b European trial of BB2603 in onychomycosis (BBTAF202). The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech...

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

17 May 2022

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the UK Medicines and Healthcare...

Maxwellia appoints Ian Adamson as Strategic Advisor

16 May 2022

Maxwellia appoints Ian Adamson as Strategic Advisor

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a...

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

28 April 2022

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

28 April 2022 - Manchester, UK. The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding package for Panthera from Business...